Answers are grounded in this paper and cite their sources.
Case report reveals improvement in immune-mediated necrotizing myopathy with intravenous immunoglobulin, highlighting treatment considerations.
Inflammatory myopathies present with proximal muscle weakness and elevated creatine kinase levels. Immune-mediated necrotizing myopathy (IMNM) is distinguished by muscle necrosis with minimal lymphocytic infiltrates on biopsy. Those with IMNM may have the signal recognition particle (SRP) antibody, hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibody, or neither. We present a case of anti-SRP-positive IMNM in a patient with chronic proximal muscle weakness and dysphagia, which improved with empiric intravenous immunoglobulin. Muscle biopsy showed major histocompatibility complex-I positivity, confirming immune-mediated necrotizing myopathy. Ongoing steroid treatment with physical rehabilitation and neurology follow-up is planned. Although corticosteroids remain standard first-line therapy, early intravenous immunoglobulin or rituximab should be considered in statin-naive anti-HMGCR and anti-SRP disease. Cardiac screening is recommended given the frequency of extramuscular cardiac involvement in IMNM.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: